Research
Energy balance
Participants receiving cagrilintide-semaglutide were more likely to achieve weight-loss targets of 5%, 20%, 25%, and 30% or more compared to placebo.
Cagrilintide-semaglutide may help patients achieve significant weight-loss goals.
StrongSupportsmedium confidence
Participants receiving cagrilintide-semaglutide were more likely than those receiving placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more, and 30% or more.
Why this rating
Based on a phase 3a, multicenter, double-blind, placebo-controlled trial.
Source
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
W. Timothy Garvey et al. · New England Journal of Medicine · 2025
rct · n=3417Cited 138×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →